Kornimate/medical-research-clean huggingface dataset:
depot disulfiram for aids and arc

Conditions: HIV Infections

Summary: to assess the safety and efficacy of depot disulfiram as a new treatment for aids and aids related complex.


Eligibility criteria:
inclusion criteria patients must have a positive diagnosis of aids or aids related complex (arc) according to the cdc criteria. * also patient must be: * able to understand the study. * strongly motivated to participate in the study, and willing to comply with all the conditions specified in the informed consent forms. * ambulatory and able to maintain an independent life outside the hospital. * free of clinically significant organic disease affecting neurologic, hepatic, renal, and clinical status. patients must be free of clinically significant organic disease affecting neurologic, hepatic, renal, and clinical status. patients must be free of clinically significant organic disease affecting neurologic, hepatic, renal, and clinical status. history of alcohol abuse.

Keywords: delayed-action preparations disulfiram acquired immunodeficiency syndrome aids-related complex
high-flow nasal oxygen therapy in hospitalized infant with moderate-to-severe bronchiolitis

Conditions: Bronchiolitis

Summary: over the last decade, high-flow nasal oxygen therapy (hfn) has emerged as a new method to provide respiratory support in children with moderate to severe bronchiolitis. however, any randomized clinical trial (rct) have demonstrated that earlier support with hfn is superior to standard care including low -flow nasal oxygen therapy to reduce the risk of acute respiratory failure requiring non invasive (or tracheal) ventilation and subsequently the need of picu transfer.

open label, non-blinded multi-centre, randomised controlled trial comparing standard care including oxygen delivery via hfn versus standard nasal oxygen therapy in infants admitted to hospital with moderate-to-severe bronchiolitis.

Eligibility criteria:
inclusion criteria: * first episode of hospitalised bronchiolitis (as defined by american academy of pediatrics clinical criterions ) * aged 7 days- 6 months * transcutaneous spo2 in room air \< 95% * modified wood's clinical asthma score (m-wcas) ≥ 2 et ≤ 5 * agreement of at least one of the parents or legal tutor for his child to participate in biomedical research * affiliation to social security (beneficiary or entitled), except beneficiary of state medical help exclusion criteria: * urgent need for mechanical ventilation support either by ncpap ou endotracheal route * severe form defined by modified wood's clinical asthma score (mwcas) exceeding 5 or 6, requiring non invasive ventilation (n cpap) * uncorrected cyanotic heart disease, innate immune deficiency, cranio-facial malformation, congenital stridor, tracheotomy * inclusion in other observational study.

Keywords: infant oxygen therapy high flow nasal canula oxygen therapy bronchiolitis
comparison of low dose versus high dose cyclophosphamide as induction therapy in the treatment of lupus nephritis

Conditions: Lupus Nephritis

Summary: this study will be conducted to find out whether low dose or high dose cyclophosphamide therapy is effective in the treatment of proliferative lupus nephritis.it will also compare the side effects and risks of infection in low dose and high dose cyclophosphamide group. half of the participants will receive a low dose cyclophosphamide for 3 months and half will receive high dose cyclophosphamide therapy monthly for 6 months followed by azathioprine 2 mg/kg.

the study will be conducted at the department of clinical immunology, jawaharlal institute of postgraduate medical education \& research (jipmer). once the patients are diagnosed to have systemic lupus erythematosus (sle) lupus nephritis and they satisfy the inclusion criteria , they will be informed about the nature and severity of the disease and about the expected treatment options and the duration of treatment. after providing written informed consent, eligible patients will be stratified into two groups. block randomization will be done to generate random allocation sequence.they will receive either a low dose or high dose cyclophosphamide as per the protocol mentioned below: group i : low dose arm : intravenous cyclophosphamide fixed pulse 500 mg each 2 weekly total 6 doses followed by azathioprine 2 mg/kg. group ii : high dose arm : intravenous cyclophosphamide therapy 750 mg/m2 will be given every 4 weekly for total 6 doses followed by azathioprine 2 mg/kg. intravenous methylprednisolone pulses 1 gm each will be given for 3 days in both the treatment arms followed by prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks. additional drugs as per indication like hydroxychloroquine, antihypertensives and cotrimoxazole prophylaxis shall also be given unless contraindicated. there will be monitoring of treatment efficacy and side effects in each treatment arm

Eligibility criteria:
inclusion criteria: 1. a diagnosis of sle according to the american college of rheumatology (acr) criteria 2. age \>16 years 3. proteinuria ≥500 mg in 24 hours/ urine routine microscopy showing active cellular casts/sediments. 4. biopsy-proven proliferative lupus glomerulonephritis of class iii, iv according to the international society of nephrology/renal pathology society (isn/rps) criteria. exclusion criteria: 1. patients ever treated previously with intravenous or oral cyclophosphamide or received steroids \>15mg/day in the last 3 months. 2. patients with renal thrombotic microangiopathy, preexisting chronic renal failure, pregnancy, previous malignancy (except skin and cervical intraepithelial neoplasia), diabetes mellitus or coronary heart disease. 3. patients with previously documented severe toxicity to immunosuppressive drugs. 4. patients with acute/chronic infections. 5. pregnancy
integrative medicine consultation for patients with pain or fatigue

Conditions: Pain; Fatigue

Summary: patients with a diagnosis of chronic fatigue or pain benefit minimally from a conventional medical evaluation yet consume a large amount of medical resources and time. the question is to see if patients with a diagnosis of chronic pain or fatigue benefit from an integrative medicine medical evaluation conducted by physician who has additional training in integrative medicine. patients who call for a general medical examination with a complaint of chronic fatigue or pain will be set up with the integrative medical specialist or standard general medical evaluation.


Eligibility criteria:
* patients seeking a medical evaluation for a primary complaint of pain or fatigue.
a clinical study for magnetic stimulation of the posterior tibial nerve in overactive bladder

Conditions: Overactive Bladder

Summary: to evaluate the safety and feasibility of non-invasive magnetic stimulation of the posterior tibial nerve using the emkinetics lofit pulse system for treating patients with documented overactive bladder.


Eligibility criteria:
inclusion criteria: * women \>18 years of age * a score of \> 4 on the oab-q short form for urgency (question 1) * average urinary frequency \> 10 times in one 24 hour day based on a 3-day voiding diary * self-reported bladder symptoms present \> 3 months * self-reported failed conservative care (e.g., dietary restriction, fluid restriction, bladder training, behavioral modification, pelvic muscle training, biofeedback, etc.) or use of antimuscarinics. * off all anti-muscarinics for at least 2 weeks prior to enrollment * capable of giving informed consent * ambulatory and able to use a toilet independently, without difficulty * capable and willing to follow all study-related procedures exclusion criteria: * the patient is pregnant or intends to become pregnant during the course of the study. (patients becoming pregnant during the course of the study will immediately be terminated from the study.) * the patient has an active urinary tract infection. * neurogenic bladder * botox use in bladder or pelvic floor muscles in the past year * pacemakers or implantable defibrillators * primary complaint of stress urinary incontinence * current vaginal infection * current use of interstim * current use of bion * current use of tens in the pelvic region, back or leg * previously been treated with ptns * use of investigational drug/device therapy within the past 4 weeks * participating or have participated within the past 4 weeks in any clinical investigation involving or impacting gynecologic, urinary or renal function * deemed unsuitable for enrollment in study by the investigators based on subjects' history or physical examination * the patient has metal implant from surgery or a metallic foreign body in either leg below (distal to) the knee (or permanent metallic tattoo \<30cm from left ankle). * the patient has chronic constipation (less than two (2) bowel movements per week) * the patient has history of gastric or urinary retention * the patient has uncontrolled diabetes * subjects with nerve damage, injury or surgery that would impact either tibial nerve or pelvic floor function * the patient is unable or unwilling to sign informed consent * the patient is currently on pharmacologic treatment that could affect bladder function * known cystocele \>/= to grade 3 that has not been reduced by treatment (surgery or pessary)
urdu translation of bimanaual fine motor functional classification system 2

Conditions: Cerebral Palsy

Summary: in 2002, beckung and hagberg introduced the bimanual fine motor function (bfmf) classification system. however, the initial version struggled to clearly distinguish between its five defined levels. despite this, the bfmf system aimed to align with the gross motor function classification system (gmfcs) levels. since its introduction, the bfmf system has been widely utilized in the surveillance of cerebral palsy in europe (scpe) registry and various epidemiological studies

beckung and hagberg developed the bimanual fine motor function (bfmf) classification system in 2002. although the initial version had limitations in clearly differentiating between its five levels, it aimed to align with the gross motor function classification system (gmfcs). since then, the bfmf system has been widely used in the surveillance of cerebral palsy in europe (scpe) registry and various epidemiological studies. the bfmf is a five-level ordinal scale, ranging from level i (best performance) to level v (most limited function), designed to assess the ability of children with cerebral palsy to use both hands together to handle objects. evaluation is based on observation of bimanual performance and parental reports of usual performance. this study consists of two parts: a pilot study for physiotherapists, with defined inclusion and exclusion criteria, and a main study involving cerebral palsy patients, using a finalized urdu version of the questionnaire to collect data.

Eligibility criteria:
inclusion criteria: * age: 8-15 years * gender: both male and female patients * type of cp: diplegic, athetoid, ataxic, and spastic forms * gross motor function classification system (gmfcs) level: 2 or 3 exclusion criteria: * - orthopedic conditions such as fractures or rickets * systemic disorders, including inflammatory diseases and autoimmune conditions * psychological and behavioral issues.

Keywords: bimanual fine motor classification-2 cerebral palsy
mometasone and markers of airway inflammation

Conditions: Asthma

Summary: a post-marketing study to look at the effects of asmanex on markers of airway inflammation.

patients with asthma and not treated with anti-inflammatory medications were studied. this was a parallel, randomized, placebo-controlled study to investigate the effects of asmanex on markers of airway inflammation including exhaled nitric oxide, airway reactivity, fev1 and nitrates/nitrites and ph in exhaled breath condensate.

Eligibility criteria:
inclusion criteria: * asthma * non-smoker * fev1 of at least 60% predicted exclusion criteria: * pregnancy or lactation * corticosteroid use in past 30 days

Keywords: asthma nitric oxide exhaled breath condensate methacholine challenge
pilot evaluation to assess the clinical and economic impact of pfizer's pain management program (painpremier) in the treatment of low back pain, in an occupational health care setting in finland

Conditions: Back Pain

Summary: the aim of this investigation is to determine whether the use of painpremier will significantly improve function in patients with low back pain in an occupational health clinical setting. painpremier is a tool that assists clinicians in the accurate diagnosis of back pain and associated problems in order to treat them most effectively.

patients presenting at feeder sites to be referred to low back pain clinic and assessed for eligibility a decision was made to terminate this study on 09 oct 2013. the study was terminated for operational/business reasons. this study was not terminated for reasons of safety or efficacy.

Eligibility criteria:
inclusion criteria: * new episode of low back pain * member of terveystalo health insurance scheme exclusion criteria: * previous back pain related healthcare visit in the last 3 months * patients identified as having a 'red flag' condition

Keywords: non-interventional clinical investigation low back pain painpremier
effect of berberine for endothelial function and intestinal microflora in patients with coronary artery disease

Conditions: Stable Coronary Artery Disease; Percutaneous Coronary Intervention

Summary: the purpose of this study is to conduct a single-center, randomized, open-label, controlled, dose-escalating, parallel-group study, evaluating the effects and change of endothelial function and gut microbiota after berberine administration in patients with stable coronary artery disease who are at \> 8 but ≤ 40 weeks after elective percutaneous coronary intervention

in the present study, about 48 patients with stable coronary artery disease who are at \> 8 but ≤ 40 weeks after elective percutaneous coronary intervention. the total study duration is expected to be approximately 14 weeks per patient, including a screening period, a 12±1 week treatment period, randomization was computer generated. after screening, eligible subjects will be randomly assigned into one of the following two groups: berberine+therapy arm or standard therapy arm. the primary objective is to determine whether a combination of berberine and coronary artery disease standard therapy is preferable to either berberine alone or standard therapy alone. the visit schedule will be as follows: visit 1: day -7 to day -1, screening/enrolment; visit 2: day 1, randomization/first dose; visit 3: week 4±1, dose adjustment 1, bbr (100mg, tid); visit 4: week 8±1, dose adjustment 2, bbr (200mg, tid); visit 5: week 12±1, end of treatment (eot) /last dose, bbr (300mg, tid); safety visit. we perform cross-sectional comparisons between the two arms and longitudinal comparisons within each arm to evaluate the indicators as follows: 1. . endothelial function, as measured by flow mediated dilation (fmd) from baseline to 12-week follow-up; 2. . gut microbiota, as sequenced by metagenomic sequencing from baseline to 12-week follow-up. blood and feces samples will be collected before and after treatment. flow mediated dilation (fmd), hba1c, fasting plasma glucose (fpg), lipids and cholesterol level, inflammatory factors, amino acids, bile acids and other metabolic related components and parameters will be measured. furthermore, the change of gut microbiota will be evaluated too.

Eligibility criteria:
inclusion criteria: patients with stable coronary artery disease undergo elective pci \>8 weeks, but ≤40 weeks exclusion criteria: 1. planned coronary revascularization, including pci and coronary artery bypass graft (cabg) during the study period. 2. subjects with uncontrolled high blood pressure 3. recent (within 4 weeks) dose adjustment of any standard therapy agents 4. recent (within 4 weeks) use of berberine 5. history of intolerance to berberine. 6. cr\>1.5mg/dl; alt level exceeds the upper limit of 3 times 7. heart failure or lvef \<50% 8. uncontrolled arrhythmia 9. pregnancy or lactation 10. malignant tumor or life expectancy is less than half a year 11. subjects who can not complete the follow-up

Keywords: berberine gut microbiota endothelial function
prognostic value of p30 after cardiac arrest

Conditions: Out-Of-Hospital Cardiac Arrest

Summary: this study aims to examine whether p30 wave of somatosensory evoked potentials (sep) is related with outcome after cardiac arrest. the study design is a prospective, multicenter-observational study. patients survived after out-of-hospital cardiac arrest undergoing hypothermic-targeted temperature management will participate in the study. relationship of p30 wave of sep with the neurologic outcome on hospital discharge will be evaluated.

the absence of n20 of the somatosensory evoked potentials (sep) is recommended as a valuable predictor of poor neurologic outcome in post-cardiac arrest patients. however, interpretation of n20 is affected by the background noise levels. reliable analysis of n20 is limited with high noise levels and artifacts. moreover, presence of n20 does not guarantee good neurologic outcome. p30 is a positive deflection of n20 occurring on 25-35 msec. according to our pilot study, n20 without following p30 is related with poor outcome, while n20 followed by p30 is highly related with good outcome. p30 is evident even when the n20 is ambiguous in patients with good outcome. we hypothesized that the negative-positive deflection of n20-p30 components is more valuable predictor than the n20 alone. in this observational study, we will identify whether presence of p30 checked on 24 and 72 hours after cardiac arrest predicts neurologic outcome more accurately than the presence of n20 alone.

Eligibility criteria:
inclusion criteria: * comatose survivors after out-of-hospital cardiac arrest exclusion criteria: * not treated by hypothermic-targeted temperature management

Keywords: heart arrest, hypothermia, sep, prognosis
tumor regression grade as predictor of adjuvant therapy

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)

Summary: neoadjuvant therapy followed by surgery is preferred for locally advanced esophageal squamous cell carcinoma, but the necessity of adjuvant therapy remains controversial. tumor regression grade reflects the response to neoadjuvant therapy and may predict patient prognosis, yet its role in guiding adjuvant therapy remains unexplored.

we aim to explore the role of trg and other clinical characteristics in predicting the efficacy of postoperative adjuvant therapy in escc patients receiving neoadjuvant therapy. this study includes patients who underwent r0 esophagectomy for thoracic escc after neoadjuvant therapy. patients will be assessed by trg and divided into good responders (trg 0-1) and poor responders (trg 2-3). the main variable of interest is adjuvant therapy, and the primary outcome is os, defined as time from diagnosis until death. cox proportional hazards regression models will be used to calculate hazard ratios and 95% confidence intervals to assess the impact of various variables on survival time.

Eligibility criteria:
inclusion criteria: (i) underwent r0 resection with either two-field or three-field lymphadenectomy (ii) received neoadjuvant therapy such as preoperative radiotherapy, chemoradiotherapy, or combined immunotherapy (iii) had esophageal squamous cell carcinoma pathology. exclusion criteria: (i) patients with incomplete clinical data or follow-up information (ii) diagnosed with multiple primary malignancies
the renal transplant outcome prediction and validation study

Conditions: Ischemia Reperfusion Injury

Summary: the number of patients with end stage renal disease is increasing continuously and kidney transplantation is the preferred treatment modality. modern immunosuppressive therapy has reduced the number of acute rejection episodes and increased one year allograft survival dramatically. nonetheless, 4% of allografts are lost beyond the first year annually due to a multifactorial process and the latter number has not changed for decades. one of the most important factors to determine long-term success after kidney transplantation is the quality of the donor organ. for example, transplantation of organs from elderly or extended criteria donors results in reduced allograft and patient survival. in previous work, the investigators specifically focused on age-associated molecular signatures including telomere length and mrna expression levels of the cell cycle inhibitors cdkn2a (p16ink4a) and cdkn1a (p21waf1) and assessed these parameters in pre-implantation biopsies of 54 patients. in a linear regression analysis cdkn2a turned out to be the best single predictor for serum creatinine after 1 year followed by donor age and telomere length. a multiple linear regression analysis revealed that the combination of cdkn2a values and donor age yielded even higher predictive values. in another study the investigators were able to show an interaction between donor age and use of calcineurin inhibitors with regard to outcome after renal transplantation. during these past activities an extensive set of whole genome transcriptomics profile information from zero hour biopsies and clinical follow-up data has been collected. in the topvas study, existing data derived from 72 of the above mentioned set of biopsies (exclusion of live donor grafts) will be analysed with state of the art bioinformatical/system biology tools to derive a general (not purely age associated) prognostic biomarker panel for functional transplant outcome two years after transplantation. this marker panel will also be used to define organs preferentially suitable for mmf/tacrolimus based immunosuppression. both panels will then be validated for their prognostic and predictive information on the long-term outcome after transplantation in a new independent patient population treated with tacrolimus and mmf. in addition to biomarker assessment and in pursue of identifying alternative and/or complementary parameters with predictive value , an advanced morphological investigation of tissue biopsy life stains will be performed employing an innovative cell viability staining technology ("biopsychronology").


Eligibility criteria:
inclusion criteria: * written informed consent * recipient age \> 18 years * first or second deceased donor kidney transplantation * panel reactive antibody frequency \<50% exclusion criteria: * combined kidney transplantation with another organ * living donor kidney transplantation * topvas is a interventional prospective cohort study and participation of patients in other randomized prospective interventional trials does not per se violate the protocol